TNYA

SEC source: 0001193125-26-389563 · ownership.xml · derivative · entry 2

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 732,500

Underlying: Common Stock · 732,500 shares

Expires 2036-09-09

F4 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested.

SEC source: 0001193125-26-389563 · ownership.xml · nonDerivative · entry 1

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 539,782

F1 · security: Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on February 15, 2027, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested.

F3 · balance_after: Includes 384,069 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-389561 · ownership.xml · derivative · entry 2

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 293,000

Underlying: Common Stock · 293,000 shares

Expires 2036-09-09

F4 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested.

SEC source: 0001193125-26-389561 · ownership.xml · nonDerivative · entry 1

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 263,073

F1 · security: Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on February 15, 2027, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested.

F3 · balance_after: Includes 142,076 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-354518 · ownership.xml · nonDerivative · entry 4

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 417,782

F8 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 3, 2026.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $.6820 to $.7253. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F9 · balance_after: Includes 262,069 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-354518 · ownership.xml · nonDerivative · entry 3

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 425,188

F6 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $.6820 to $.7253. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F7 · balance_after: Includes 281,894 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-354518 · ownership.xml · nonDerivative · entry 2

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 430,208

F4 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $.6820 to $.7253. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F5 · balance_after: Includes 295,331 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-354518 · ownership.xml · nonDerivative · entry 1

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 434,177

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $.6820 to $.7253. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3 · balance_after: Includes 305,956 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-354517 · ownership.xml · nonDerivative · entry 4

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 214,073

F8 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 3, 2026.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $.6820 to $.7253. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F9 · balance_after: Includes 93,076 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-354517 · ownership.xml · nonDerivative · entry 3

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 216,352

F6 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on January 24, 2025.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $.6820 to $.7253. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F7 · balance_after: Includes 99,169 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-354517 · ownership.xml · nonDerivative · entry 2

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 218,223

F4 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $.6820 to $.7253. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F5 · balance_after: Includes 104,169 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-354517 · ownership.xml · nonDerivative · entry 1

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 219,860

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $.6820 to $.7253. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3 · balance_after: Includes 108,544 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 6,000 shares of common stock acquired pursuant to the Tenaya Therapeutics, Inc. 2021 Employee Stock Purchase Plan on June 10, 2026.

SEC source: 0001193125-26-303681 · ownership.xml · derivative · entry 1

Hyllengren Eric J · CIK 0001966926 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,650,000

Underlying: Common Stock · 1,650,000 shares

Expires 2036-07-12

F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2024 Inducement Equity Incentive Plan. Option will vest as to 1/4th of the total number of shares subject to the option on the one-year anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested.

SEC source: 0001193125-26-249052 · ownership.xml · derivative · entry 1

Burroughs Amy L. · CIK 0001872564 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2036-05-27

F1 · derivative.exercise_date: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

SEC source: 0001193125-26-249135 · ownership.xml · derivative · entry 1

Williams R Sanders · CIK 0001375347 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2036-05-27

F1 · derivative.exercise_date: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

SEC source: 0001193125-26-249132 · ownership.xml · derivative · entry 1

Walsh Jeffrey T. · CIK 0001578251 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2036-05-27

F1 · derivative.exercise_date: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

SEC source: 0001193125-26-249114 · ownership.xml · derivative · entry 1

Parschauer Karah Herdman · CIK 0001677455 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2036-05-27

F1 · derivative.exercise_date: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

SEC source: 0001193125-26-249113 · ownership.xml · derivative · entry 1

Lee June · CIK 0001696493 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2036-05-27

F1 · derivative.exercise_date: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

SEC source: 0001193125-26-249131 · ownership.xml · derivative · entry 1

Stehman-Breen Catherine · CIK 0001702233 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2036-05-27

F1 · derivative.exercise_date: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

SEC source: 0001193125-26-249116 · ownership.xml · derivative · entry 1

Srivastava Deepak · CIK 0001868501 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2036-05-27

F1 · derivative.exercise_date: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

SEC source: 0001193125-26-231315 · ownership.xml · nonDerivative · entry 1

Higa Tomohiro · CIK 0002054280 · SVP, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,267

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on August 15, 2024.

F2 · balance_after: Includes 67,938 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-231324 · ownership.xml · nonDerivative · entry 1

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 440,014

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025.

F2 · balance_after: Includes 321,581 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-231323 · ownership.xml · nonDerivative · entry 1

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 215,497

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on January 24, 2025.

F2 · balance_after: Includes 112,919 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-076814 · ownership.xml · nonDerivative · entry 4

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.641, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F3 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

SEC source: 0001193125-26-076814 · ownership.xml · nonDerivative · entry 3

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.641, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

SEC source: 0001193125-26-076814 · ownership.xml · nonDerivative · entry 2

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,862,545

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.584 to $0.6392, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F3 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

SEC source: 0001193125-26-076814 · ownership.xml · nonDerivative · entry 1

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,649,281

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.584 to $0.6392, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

SEC source: 0001193125-26-067007 · ownership.xml · nonDerivative · entry 4

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 2,211,757

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.573 to $0.6225, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F3 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

SEC source: 0001193125-26-067007 · ownership.xml · nonDerivative · entry 3

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,958,509

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.573 to $0.6225, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

SEC source: 0001193125-26-067007 · ownership.xml · nonDerivative · entry 2

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 2,374,048

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.60 to $0.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F3 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

SEC source: 0001193125-26-067007 · ownership.xml · nonDerivative · entry 1

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 2,102,218

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.60 to $0.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

SEC source: 0001193125-26-055445 · ownership.xml · nonDerivative · entry 3

Higa Tomohiro · CIK 0002054280 · SVP, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,752

F6 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on January 24, 2025.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F7 · balance_after: Includes 71,688 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-055445 · ownership.xml · nonDerivative · entry 2

Higa Tomohiro · CIK 0002054280 · SVP, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,774

F4 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F5 · balance_after: Includes 76,376 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-055445 · ownership.xml · nonDerivative · entry 1

Higa Tomohiro · CIK 0002054280 · SVP, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,610

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3 · balance_after: Includes 78,314 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-055442 · ownership.xml · nonDerivative · entry 3

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 443,404

F6 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F7 · balance_after: Includes 330,187 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-055442 · ownership.xml · nonDerivative · entry 2

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 448,436

F4 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F5 · balance_after: Includes 343,625 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-055442 · ownership.xml · nonDerivative · entry 1

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 452,415

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3 · balance_after: Includes 354,250 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-055439 · ownership.xml · nonDerivative · entry 3

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 218,618

F6 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on January 24, 2025.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F7 · balance_after: Includes 120,838 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-055439 · ownership.xml · nonDerivative · entry 2

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,494

F4 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F5 · balance_after: Includes 125,838 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-055439 · ownership.xml · nonDerivative · entry 1

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 222,136

F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3 · balance_after: Includes 130,213 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 5,102 shares of common stock acquired pursuant to the Tenaya Therapeutics, Inc. 2021 Employee Stock Purchase Plan on December 10, 2025.

SEC source: 0001193125-26-049028 · ownership.xml · nonDerivative · entry 4

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 2,651,817

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.65 to $0.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F3 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

SEC source: 0001193125-26-049028 · ownership.xml · nonDerivative · entry 3

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 2,348,183

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.65 to $0.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

SEC source: 0001193125-26-049028 · ownership.xml · nonDerivative · entry 2

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 4,803,275

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.80 to $0.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F3 · ownership.nature: The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

SEC source: 0001193125-26-049028 · ownership.xml · nonDerivative · entry 1

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 4,253,298

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.80 to $0.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

SEC source: 0001193125-26-039768 · ownership.xml · derivative · entry 2

Higa Tomohiro · CIK 0002054280 · SVP, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,500

Underlying: Common Stock · 175,500 shares

Expires 2036-02-02

F4 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested.

SEC source: 0001193125-26-039768 · ownership.xml · nonDerivative · entry 1

Higa Tomohiro · CIK 0002054280 · SVP, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,221

F1 · security: Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on August 15, 2026, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested.

F3 · balance_after: Includes 79,720 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-039760 · ownership.xml · derivative · entry 2

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 952,250

Underlying: Common Stock · 952,250 shares

Expires 2036-02-02

F4 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested.

SEC source: 0001193125-26-039760 · ownership.xml · nonDerivative · entry 1

Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 458,266

F1 · security: Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on August 15, 2026, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested.

F3 · balance_after: Includes 369,875 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001193125-26-039763 · ownership.xml · derivative · entry 2

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 318,500

Underlying: Common Stock · 318,500 shares

Expires 2036-02-02

F4 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested.

SEC source: 0001193125-26-039763 · ownership.xml · nonDerivative · entry 1

Tingley Whittemore · CIK 0001868494 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 223,778

F1 · security: Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on August 15, 2026, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested.

F3 · balance_after: Includes 134,588 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.